Episodes
Wednesday Sep 07, 2022
Innovating Clinical Trials: Real World Data in Drug Development
Wednesday Sep 07, 2022
Wednesday Sep 07, 2022
Randomized clinical trials are the gold standard for evaluating the efficacy and safety of medicines, but they come with many drawbacks including high monetary and time costs, a lack of representation compared to the general public, and ethical limitations. Historically, these trials were the main mechanism to understand the effects of a medicine. But more recently, real world data from sources such as electronic health records, insurance claims and billing activities, disease registries, and wearable devices, is having a greater effect on understanding a medicine’s usage and effects. Although this information is collected outside of clinical trials, clinical researchers incorporate it during the earliest phases of clinical development to gain additional information and speed up the drug development process.
In this episode, we talk to Brian Bradbury, vice president of the Center for Observational Research at Amgen, about the increased utilization of real world data and its potential to revolutionize every stage of clinical research, from trial design to regulatory requirements to outcomes measurement.
To dive further into this topic, please join Amgen scientists at the Innovating Clinical Trials Q&A webinar discussion on September 28, 2022. Register for the event here.
Welcome to Innovating Clinical Trials, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress. In this series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop optimal medicines that benefit patients.
Wednesday Aug 31, 2022
Innovating Clinical Trials: Operational Innovation
Wednesday Aug 31, 2022
Wednesday Aug 31, 2022
Welcome to Innovating Clinical Trials, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress. In this series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop optimal medicines that benefit patients.
Our understanding of human biology and disease is progressing at an unprecedented pace, and clinical trial development and execution needs to evolve just as quickly to deliver potentially lifesaving medicines to patients who can't wait. We also need to recruit underrepresented patients into trials, which requires us to think differently about how we identify and recruit patients.
In this episode, we talk to Cynthia Verst, president of Design and Delivery Innovation for Research & Development Solutions at IQVIA, a global provider of advanced analytics, technology solutions, and clinical research services. We discuss the drivers for applying innovation in the trial execution space and how the clinical trials model is evolving across the industry thanks to modern innovations.
To dive further into this topic, please join Amgen scientists at the Innovating Clinical Trials Q&A webinar discussion on September 28, 2022. Register for the event here.
Wednesday Jul 13, 2022
The Generative Biology Revolution: Accelerating Drug Discovery with Protein Design
Wednesday Jul 13, 2022
Wednesday Jul 13, 2022
The ability to design proteins to perform desired functions will transform drug development. In particular, with AI and machine learning, scientists gain the ability to engineer antibody-based drugs, including multispecifics which engage multiple targets. By altering existing protein structures or developing proteins de novo, biologics will become more effective and specific.
In this episode, we talk to Suzanne Edavettal, the executive director of Protein Engineering at Amgen. We discuss how protein design affects drug development and success rates in the clinic today and in the future.
To dive further into this topic, please join Amgen scientists at the Generative Biology Q&A webinar discussion on July 20th, 2022. Register for the event here.
The Generative Biology Revolution is a special edition podcast series produced by The Scientist’s Creative Services Team.
This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Generative biology is a revolutionary approach to drug discovery and development that leverages machine learning and AI to design novel protein therapeutics. It holds the potential to enhance the speed and efficiency of discovery. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, discusses how generative biology is transforming drug discovery to make it more predictable, shorten timelines, and increase success rates of bringing life-saving medicines to patients who need them most.
Wednesday Jul 06, 2022
The Generative Biology Revolution: Protein Design from Scratch
Wednesday Jul 06, 2022
Wednesday Jul 06, 2022
Naturally-occurring proteins have evolved over millions of years to perform specific functions based on their sequences and folded structures. As our understanding of science advanced, researchers began designing proteins from scratch to solve new challenges that modern societies face.
In this episode, we talk to David Baker, director of the Institute for Protein Design at the University of Washington and one of the creators of the RoseTTAFold protein structure prediction tool. We discuss how to design proteins with sequences and structures that impart novel functions and how designed proteins will revolutionize drug development.
To dive further into this topic, please join Amgen scientists at the Generative Biology Q&A webinar discussion on July 20th, 2022. Register for the event here.
The Generative Biology Revolution is a special edition podcast series produced by The Scientist’s Creative Services Team.
This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Generative biology is a revolutionary approach to drug discovery and development that leverages machine learning and AI to design novel protein therapeutics. It holds the potential to enhance the speed and efficiency of discovery. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, discusses how generative biology is transforming drug discovery to make it more predictable, shorten timelines, and increase success rates of bringing life-saving medicines to patients who need them most.
Wednesday Jun 29, 2022
The Generative Biology Revolution: The Protein Structure Prediction Problem
Wednesday Jun 29, 2022
Wednesday Jun 29, 2022
To build better biologic drugs, researchers need to understand exactly how amino acid building blocks interact with one another and fold into functional proteins. This knowledge provides insights into how to engage a drug target or develop an optimal therapeutic. Determining a protein’s structure is a laborious process in the wet lab, but thanks to machine learning, scientists can now use various algorithms to predict structure.
In this episode, we talk to Mike Nohaile, chief scientific officer at Generate Biomedicines. Since early 2022, Amgen and Generate Biomedicines have been collaborating to discover and create protein therapeutics across several therapeutic areas and multiple modalities, including monoclonal and bispecific antibody drugs. We discuss the challenge of predicting a protein’s structure from its sequence and the steps drug developers are now taking to create novel structures with therapeutic potential using generative biology.
To dive further into this topic, please join Amgen scientists at the Generative Biology Q&A webinar discussion on July 20th, 2022. Register for the event here.
The Generative Biology Revolution is a special edition podcast series produced by The Scientist’s Creative Services Team.
This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Generative biology is a revolutionary approach to drug discovery and development that leverages machine learning and AI to design novel protein therapeutics. It holds the potential to enhance the speed and efficiency of discovery. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, discusses how generative biology is transforming drug discovery to make it more predictable, shorten timelines, and increase success rates of bringing life-saving medicines to patients who need them most.
Wednesday Jun 22, 2022
The Generative Biology Revolution: The Cresting Wave of Transformational Science
Wednesday Jun 22, 2022
Wednesday Jun 22, 2022
In 2021, the world changed for drug research and discovery when researchers published advances that used AI and machine learning to predict the structure of human proteins from their sequences. With discoveries like this, scientists are launching the generative biology revolution where they strive to leave the guesswork behind and instead use computers to quickly tailor biological molecules for therapeutic purposes. In this episode, we speak with Alan Russell, vice president of Biologics at Amgen and review what generative biology is and how it helps scientists understand proteins from their amino acid building blocks to their folded, three-dimensional structures. We also discuss how this new field improves the quality and complexity of biologic drug candidates and the speed with which researchers generate them.
To dive further into this topic, please join Amgen scientists at the Generative Biology Q&A webinar discussion on July 20th, 2022. Register for the event here.
Welcome to The Generative Biology Revolution, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Generative biology is a revolutionary approach to drug discovery and development that leverages machine learning and AI to design novel protein therapeutics. It holds the potential to enhance the speed and efficiency of discovery. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, discusses how generative biology is transforming drug discovery to make it more predictable, shorten timelines, and increase success rates of bringing life-saving medicines to patients who need them most.
Monday May 23, 2022
Transporting Laboratories into the Future with Smart Technology
Monday May 23, 2022
Monday May 23, 2022
As smart devices become commonplace in many homes, they also enter life science laboratories with the promise to enhance productivity, simplify collaborations, and produce reliable results. In this episode, Niki Spahich from The Scientist’s Creative Services team spoke with experts from MilliporeSigma about how smart devices change research for the better.
LabTalk is a special edition podcast produced by The Scientist's Creative Services Team, where we explore topics at the leading edge of innovative research. This month’s episode is sponsored by MilliporeSigma.
Monday Nov 29, 2021
Phagocidal Macrophages: A New Battle Tactic Against Resistant Cancers
Monday Nov 29, 2021
Monday Nov 29, 2021
Cancer immunotherapies are saving lives, but researchers still have a long journey ahead of them. Many cancers that are initially sensitive to immunotherapy acquire resistance over time, while others are resistant from the beginning.
In this episode, Niki Spahich from The Scientist’s Creative Services team spoke with Stephanie Dougan, an associate professor of immunology at Harvard Medical School and a principal investigator at Dana Farber Cancer Institute, about her research developing new immunotherapies for resistant tumors.
LabTalk is a special edition podcast produced by The Scientist’s Creative Services Team, where we explore topics at the leading edge of innovative research. This month’s episode is sponsored by 10x Genomics.
Wednesday Nov 17, 2021
Undruggable: Induced Proximity for Cancer and Beyond
Wednesday Nov 17, 2021
Wednesday Nov 17, 2021
Induced proximity makes it possible for scientists to attack undruggable targets by designing medicines that go beyond what conventional drugs can accomplish. Within the next decade, this work could yield new options for treatments for cancer and other diseases that currently have poor prognoses. People whose serious diseases don’t respond to conventional medicines, or who run out of options, may see induced proximity drugs come to the rescue. In this episode, Ray Deshaies is joined by David Reese, executive vice president of Research and Development at Amgen. Dave is responsible for Amgen’s entire pipeline of potential therapies, and he has had a long-standing interest in oncology, both at Amgen and in his pre-Amgen career in academic research and medical practice.
Undruggable is a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Beginning with the introduction of aspirin at the start of the 20th century, there have been three major waves of innovation in drug discovery. While breakthrough discoveries have been made, 85% of disease targets are still considered undruggable, which represents an ongoing barrier to discovering medicines for complex diseases like cancer and autoimmune conditions. Ray Deshaies, who has spent decades in academic research and is a senior vice president at Amgen, believes that the fourth wave of innovation is here, led by new types of multispecific medicines that will radically alter our concept of how drugs can work and pave the way for new solutions.
Wednesday Nov 10, 2021
Undruggable: The Emerging Induced Proximity Toolkit
Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
PROTACs have taken center stage in the effort to drug the undruggable. Researchers are now exploring other types of TACs to degrade or alter undruggable targets by bringing them together with effector proteins. In this episode, Ray Deshaies talks to Carolyn Bertozzi, professor of chemistry at Stanford University, about alternative induced proximity platforms. Notably, her research centers around lysosome targeting chimeras, or LYTACs, that target extracellular proteins for degradation by the endosome-lysosome pathway.
To dive further into this topic, please join Amgen scientists at the Undruggable Q&A webinar discussion on November 17, 2021. Register for this event here: Undruggable Q&A
Undruggable is a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Beginning with the introduction of aspirin at the start of the 20th century, there have been three major waves of innovation in drug discovery. While breakthrough discoveries have been made, 85% of disease targets are still considered undruggable, which represents an ongoing barrier to discovering medicines for complex diseases like cancer and autoimmune conditions. Ray Deshaies, who has spent decades in academic research and is a senior vice president at Amgen, believes that the fourth wave of innovation is here, led by new types of multispecific medicines that will radically alter our concept of how drugs can work and pave the way for new solutions.